Robin L. Jones

Research interests

Publications

• Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.08.1995

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30168-6

• Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

  JAMA · 2020 · https://doi.org/10.1001/jama.2020.1707

• Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30451-4

• The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

  European Journal of Cancer · 2020 · 10.1016/j.ejca.2019.11.013

• Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30269-2

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx323

• Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30381-9

• T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas

  Cancer · 2017 · https://doi.org/10.1002/cncr.30726

• Clinical and Molecular Spectrum of Liposarcoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.74.9598

• Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx054

• Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)30587-6

• Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.62.4734

• Multiple drivers of decline in the global status of freshwater crayfish (Decapoda: Astacidea)

  Philosophical Transactions of the Royal Society B Biological Sciences · 2015 · https://doi.org/10.1098/rstb.2014.0060

• Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity

  Cell Reports · 2014 · https://doi.org/10.1016/j.celrep.2013.12.041

• The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

  Breast Cancer Research and Treatment · 2008 · https://doi.org/10.1007/s10549-008-0081-7

• Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis

  Clinical Cancer Research · 2007 · https://doi.org/10.1158/1078-0432.ccr-06-1371

• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  Breast Cancer Research and Treatment · 2007 · https://doi.org/10.1007/s10549-007-9756-8

• Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

  The Lancet Oncology · 2007 · https://doi.org/10.1016/s1470-2045(07)70175-4

• Differential sensitivity of liposarcoma subtypes to chemotherapy

  European Journal of Cancer · 2005 · https://doi.org/10.1016/j.ejca.2005.07.023

• Treatment outcome with sex offenders

  Clinical Psychology Review · 1991 · https://doi.org/10.1016/0272-7358(91)90119-f

Current projects

No projects listed.